Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA
holds great promise as a safe treatment option in patients with metastasized castration …

Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …

The objective of this study was to determine prospectively the efficacy profile of 2 activity
regimens of 177Lu-PSMA therapy in patients with progressive metastatic castrate-resistant …

Purpose The aim of this study was to evaluate the efficacy and safety of 177 Lu-PSMA-617
radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). Methods In …

Background Despite progress in treatment of metastatic castration-resistant prostate cancer
(mCRPC), new approaches are urgently needed. Recently theranostic concepts using …

Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …